Literature DB >> 26637876

GSKJ4, A Selective Jumonji H3K27 Demethylase Inhibitor, Effectively Targets Ovarian Cancer Stem Cells.

Hirotsugu Sakaki1, Masashi Okada2, Kenta Kuramoto3, Hiroyuki Takeda4, Hikaru Watarai5, Shuhei Suzuki4, Shizuka Seino6, Manabu Seino1, Tsuyoshi Ohta7, Satoru Nagase7, Hirohisa Kurachi8, Chifumi Kitanaka9.   

Abstract

BACKGROUND/AIM: Global increase in the trimethylation of histone H3 at lysine 27 (H3K27me3) has been associated with the differentiation of normal stem cells and cancer cells, however, the role of H3K27me3 in the control of cancer stem cells (CSCs) remains poorly understood. We investigated the impact of increased H3K27me3 on CSCs using a selective H3K27 demethylase inhibitor GSKJ4.
MATERIALS AND METHODS: The effect of GSKJ4 on the viability as well as on the self-renewal and tumor-initiating capacity of CSCs derived from the A2780 human ovarian cancer cell line was examined.
RESULTS: GSKJ4 induced cell death in A2780 CSCs at a concentration non-toxic to normal human fibroblasts. GSKJ4 also caused loss of self-renewal and tumor-initiating capacity of A2780 CSCs surviving GSKJ4 treatment.
CONCLUSION: Our findings suggest that H3K27 methylation may have an inhibitory role in the maintenance of CSCs and that GSKJ4 may represent a novel class of CSC-targeting agents. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  JMJD3; UTX; cancer treatment; epigenetic; histone modification; xenograft analysis

Mesh:

Substances:

Year:  2015        PMID: 26637876

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  25 in total

Review 1.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

2.  Chemotherapy-induced S100A10 recruits KDM6A to facilitate OCT4-mediated breast cancer stemness.

Authors:  Haiquan Lu; Yangyiran Xie; Linh Tran; Jie Lan; Yongkang Yang; Naveena L Murugan; Ru Wang; Yueyang J Wang; Gregg L Semenza
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

Review 3.  Emerging roles of JMJD3 in cancer.

Authors:  Maryam Farzaneh; Zeinab Kuchaki; Fatima Rashid Sheykhahmad; Seyed Mohammadmahdi Meybodi; Yusef Abbasi; Effat Gholami; Farhoodeh Ghaedrahmati; Omid Anbiyaee
Journal:  Clin Transl Oncol       Date:  2022-03-03       Impact factor: 3.405

4.  Jumonji Domain-containing Protein-3 (JMJD3/Kdm6b) Is Critical for Normal Ovarian Function and Female Fertility.

Authors:  Sambit Roy; Niharika Sinha; Binbin Huang; Holly Cline-Fedewa; Norbert Gleicher; Jianrong Wang; Aritro Sen
Journal:  Endocrinology       Date:  2022-05-01       Impact factor: 5.051

5.  Inhibition of the Histone H3K27 Demethylase UTX Enhances Tumor Cell Radiosensitivity.

Authors:  Barbara H Rath; Isabella Waung; Kevin Camphausen; Philip J Tofilon
Journal:  Mol Cancer Ther       Date:  2018-02-26       Impact factor: 6.261

6.  [Association of JMJD3, MMP-2 and VEGF expressions with clinicopathological features of invasive ductal breast carcinoma].

Authors:  Xiaoyan Xu; Jianjun Wang; Chen Yan; Yingli Men; Huang Jiang; Huijuan Fang; Xianwei Xu; Jinhua Yang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-11-30

7.  GSK-J4-Mediated Transcriptomic Alterations in Differentiating Embryoid Bodies.

Authors:  Chanchal Mandal; Sun Hwa Kim; Sung Chul Kang; Jin Choul Chai; Young Seek Lee; Kyoung Hwa Jung; Young Gyu Chai
Journal:  Mol Cells       Date:  2017-10-17       Impact factor: 5.034

Review 8.  Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers.

Authors:  Gaya Punnia-Moorthy; Peter Hersey; Abdullah Al Emran; Jessamy Tiffen
Journal:  Front Genet       Date:  2021-06-16       Impact factor: 4.599

Review 9.  Drug Delivery Using Nanoparticles for Cancer Stem-Like Cell Targeting.

Authors:  Bing Lu; Xiaojia Huang; Jingxin Mo; Wei Zhao
Journal:  Front Pharmacol       Date:  2016-04-12       Impact factor: 5.810

10.  Repositioning CEP-1347, a chemical agent originally developed for the treatment of Parkinson's disease, as an anti-cancer stem cell drug.

Authors:  Masashi Okada; Hiroyuki Takeda; Hirotsugu Sakaki; Kenta Kuramoto; Shuhei Suzuki; Tomomi Sanomachi; Keita Togashi; Shizuka Seino; Chifumi Kitanaka
Journal:  Oncotarget       Date:  2017-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.